ATE464061T1 - Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen - Google Patents
Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinenInfo
- Publication number
- ATE464061T1 ATE464061T1 AT02707393T AT02707393T ATE464061T1 AT E464061 T1 ATE464061 T1 AT E464061T1 AT 02707393 T AT02707393 T AT 02707393T AT 02707393 T AT02707393 T AT 02707393T AT E464061 T1 ATE464061 T1 AT E464061T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- compositions
- cytokines
- administration
- superoxide
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title abstract 7
- 108090000695 Cytokines Proteins 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 4
- 208000001953 Hypotension Diseases 0.000 title abstract 2
- 230000036543 hypotension Effects 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 5
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 abstract 3
- 239000003054 catalyst Substances 0.000 abstract 3
- 238000007323 disproportionation reaction Methods 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 150000003943 catecholamines Chemical class 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 2
- 239000005555 hypertensive agent Substances 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 102000019197 Superoxide Dismutase Human genes 0.000 abstract 1
- 108010012715 Superoxide dismutase Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 239000013110 organic ligand Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26012001P | 2001-01-05 | 2001-01-05 | |
| PCT/US2002/000036 WO2002053142A2 (en) | 2001-01-05 | 2002-01-03 | Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE464061T1 true ATE464061T1 (de) | 2010-04-15 |
Family
ID=22987847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02707393T ATE464061T1 (de) | 2001-01-05 | 2002-01-03 | Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050175580A1 (de) |
| EP (1) | EP1347773B1 (de) |
| JP (1) | JP4331939B2 (de) |
| AT (1) | ATE464061T1 (de) |
| AU (1) | AU2002241807A1 (de) |
| DE (1) | DE60235955D1 (de) |
| WO (1) | WO2002053142A2 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2725023T3 (es) | 2006-10-12 | 2019-09-18 | Galera Labs Llc | Métodos para el tratamiento de la mucositis oral |
| US20110009416A1 (en) * | 2009-07-07 | 2011-01-13 | Sepracor Inc. | PH INDEPENDENT FORMULATIONS OF 6-(5-CHLORO-2-PYRIDYL)-5-[(4-METHYL-1-PIPERAZINYL)CARBONYLOXY]-7-OXO-6,7-DIHYDRO-5H-PYRROLO[3,4-b]PYRAZINE |
| EP2760874A4 (de) * | 2011-09-26 | 2015-04-08 | Galera Therapeutics Llc | Verfahren zur behandlung von erkrankungen |
| RS60558B1 (sr) | 2015-08-11 | 2020-08-31 | Galera Labs Llc | Pentaaza makrociklični prstenasti kompleksi koji poseduju oralnu bioraspoloživost |
| KR20180132939A (ko) | 2016-05-03 | 2018-12-12 | 갈레라 랩스, 엘엘씨 | 암 치료를 위한 조합 요법 |
| JP7166634B2 (ja) | 2016-09-01 | 2022-11-08 | ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー | ペンタアザ大環状環複合体およびアスコルビン酸化合物による組み合わせ癌療法 |
| IL295620B2 (en) | 2017-04-13 | 2024-01-01 | Galera Labs Llc | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2265387A (en) * | 1940-03-11 | 1941-12-09 | John H Mcmillin | Nasal pack |
| US2493326A (en) * | 1949-03-01 | 1950-01-03 | John H Trinder | Tampon for control of intractable nasal hemorrhages |
| US2847997A (en) * | 1956-01-13 | 1958-08-19 | James J Tibone | Catheter |
| US3049125A (en) * | 1960-03-28 | 1962-08-14 | Kriwkowitsch George | Nose packing device |
| US3420237A (en) * | 1966-09-02 | 1969-01-07 | Martha K Fortay | Process and article for the treatment of severe epistaxis |
| GB1340788A (en) * | 1971-02-04 | 1974-01-30 | Matburn Holdings Ltd | Nasal tampons |
| US4044793A (en) * | 1975-08-25 | 1977-08-30 | Shiley Laboratories, Inc. | Relief valve |
| US4338941A (en) * | 1980-09-10 | 1982-07-13 | Payton Hugh W | Apparatus for arresting posterior nosebleeds |
| US4364392A (en) * | 1980-12-04 | 1982-12-21 | Wisconsin Alumni Research Foundation | Detachable balloon catheter |
| US4638803A (en) * | 1982-09-30 | 1987-01-27 | Rand Robert W | Medical apparatus for inducing scar tissue formation in a body |
| US4619261A (en) * | 1984-08-09 | 1986-10-28 | Frederico Guerriero | Hydrostatic pressure device for bleeding control through an inflatable, stitchable and retrievable balloon-net system |
| US5248603A (en) * | 1985-09-03 | 1993-09-28 | Symbicom Aktiebolag | Superoxide dismutase |
| US4832680A (en) * | 1986-07-03 | 1989-05-23 | C.R. Bard, Inc. | Apparatus for hypodermically implanting a genitourinary prosthesis |
| US4686962A (en) * | 1986-07-03 | 1987-08-18 | Habley Medical Technology Corporation | Disposable cartridge assembly for hypodermically implanting a genitourinary prosthesis |
| US5192788A (en) * | 1988-05-23 | 1993-03-09 | Georgia State University Foundation, Inc. | Porphyrin antiviral compositions |
| US4883465A (en) * | 1988-05-24 | 1989-11-28 | Brennan H George | Nasal tampon and method for using |
| US5224497A (en) * | 1988-07-06 | 1993-07-06 | Ehlers Robert L | Method of removing diverticula in the colon |
| US4950280A (en) * | 1988-08-02 | 1990-08-21 | Brennan H George | Nasal tampon having a counter weight |
| US5100385A (en) * | 1989-01-27 | 1992-03-31 | C. R. Bard, Inc. | Fast purge balloon dilatation catheter |
| DE69023515T2 (de) * | 1989-06-28 | 1996-04-04 | David S Zimmon | Aufblasbare tamponadevorrichtungen. |
| US5061274A (en) * | 1989-12-04 | 1991-10-29 | Kensey Nash Corporation | Plug device for sealing openings and method of use |
| CA2072934C (en) * | 1991-07-19 | 2007-08-28 | Karl William Aston | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
| US5334380A (en) * | 1991-09-27 | 1994-08-02 | Board Of Regents, The University Of Texas System | Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension |
| US5176692A (en) * | 1991-12-09 | 1993-01-05 | Wilk Peter J | Method and surgical instrument for repairing hernia |
| US5696109A (en) * | 1992-12-07 | 1997-12-09 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
| US5545721A (en) * | 1992-12-21 | 1996-08-13 | Ophidian Pharmaceuticals, Inc. | Conjugates for the prevention and treatment of sepsis |
| US5312435A (en) * | 1993-05-17 | 1994-05-17 | Kensey Nash Corporation | Fail predictable, reinforced anchor for hemostatic puncture closure |
| US5486195A (en) * | 1993-07-26 | 1996-01-23 | Myers; Gene | Method and apparatus for arteriotomy closure |
| TW252045B (de) * | 1993-10-07 | 1995-07-21 | Allan L Goldstein | |
| US5545176A (en) * | 1994-05-31 | 1996-08-13 | Murtfeldt; Robert L. | Wound dilatation device |
| US5714511A (en) * | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| US5645566A (en) * | 1995-09-15 | 1997-07-08 | Sub Q Inc. | Apparatus and method for percutaneous sealing of blood vessel punctures |
| US5707355A (en) * | 1995-11-15 | 1998-01-13 | Zimmon Science Corporation | Apparatus and method for the treatment of esophageal varices and mucosal neoplasms |
| US6045788A (en) * | 1996-02-28 | 2000-04-04 | Cornell Research Foundation, Inc. | Method of stimulation of immune response with low doses of IL-2 |
| BR9707978A (pt) * | 1996-03-13 | 1999-07-27 | Monsanto Co | Complexos de ferro de ligantes macrocíclicos contendo nitrogênio eficazes como catalisadores para dismutação de superóxido |
| US6180620B1 (en) * | 1997-06-20 | 2001-01-30 | G.D. Searle & Co. | Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals |
| US6214817B1 (en) * | 1997-06-20 | 2001-04-10 | Monsanto Company | Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
-
2002
- 2002-01-03 JP JP2002554093A patent/JP4331939B2/ja not_active Expired - Lifetime
- 2002-01-03 EP EP02707393A patent/EP1347773B1/de not_active Expired - Lifetime
- 2002-01-03 DE DE60235955T patent/DE60235955D1/de not_active Expired - Lifetime
- 2002-01-03 WO PCT/US2002/000036 patent/WO2002053142A2/en not_active Ceased
- 2002-01-03 AT AT02707393T patent/ATE464061T1/de not_active IP Right Cessation
- 2002-01-03 US US10/433,290 patent/US20050175580A1/en not_active Abandoned
- 2002-01-03 AU AU2002241807A patent/AU2002241807A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP4331939B2 (ja) | 2009-09-16 |
| WO2002053142A3 (en) | 2002-12-27 |
| JP2004517113A (ja) | 2004-06-10 |
| AU2002241807A1 (en) | 2002-07-16 |
| DE60235955D1 (de) | 2010-05-27 |
| EP1347773B1 (de) | 2010-04-14 |
| WO2002053142A2 (en) | 2002-07-11 |
| EP1347773A2 (de) | 2003-10-01 |
| US20050175580A1 (en) | 2005-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200700362A1 (ru) | Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью | |
| DE60231123D1 (de) | Verfahren zur auslösung einer zytotoxischen immunantwort und dafür nützliche rekombinante affen-adenovirus-zusammensetzungen | |
| BRPI0414045A (pt) | administração de ligantes de tlr7 e pró-medicamentos dos mesmos para tratamento de infecção por vìrus de hepatite c | |
| CY1109216T1 (el) | Πεπτιδομιμητικοι αναστολεις πρωτεασης | |
| MX383644B (es) | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. | |
| AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
| ATE383168T1 (de) | Fgf-2 zur behandlung von erkrankungen der peripheralen arterien | |
| ATE539744T1 (de) | Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem | |
| IL159087A0 (en) | Bridged bicyclic compounds and pharmaceutical compositions containing the same | |
| CY1110437T1 (el) | Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c | |
| BRPI0513370A (pt) | uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv) | |
| ATE551060T1 (de) | Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen | |
| ATE500808T1 (de) | Onkolytische virustherapie | |
| MY141594A (en) | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES | |
| ATE464061T1 (de) | Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen | |
| AR022116A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa | |
| WO2003002528A3 (en) | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes | |
| EA200700433A1 (ru) | Производные бетулинола в качестве агентов против вич (вируса иммунодефицита человека) | |
| Pluta et al. | The use of interferon in medicine | |
| DE69836315D1 (de) | Verwendung von TCF-II zur Behandlung von durch Krebs verursachtem Gewichtsverlust, Anaemie und TNF-Erhöhung | |
| DE69817381D1 (de) | Zusammensetzung und diese enthaltende pharmazeutische zubereitung für die behandlung von herpes und verwandten viralen infektionen | |
| MA27187A1 (fr) | Methodes et compositions pour le traitement de la toxicite gastro-intestinale provoquee par la therapie cytoablative | |
| CN106132983B (zh) | 新型IFN-β蛋白类似物 | |
| DE69803052D1 (de) | Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt | |
| DK1150981T3 (da) | Terapeutisk necleosidforbindelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |